Cargando…

Central nervous system involvement of systemic ALK-positive histiocytosis with KIF5B-ALK fusion

ALK-positive histiocytosis is an emerging histiocytic entity that can involve a single organ or multiple organs. This disease frequently involves the central nervous system, and the importance of immunohistochemical and genetic analyses is emphasized for the accurate diagnosis of this rare entity. H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aoki, Yuzuna, Maeda, Masayuki, Kishi, Seiya, Kogue, Ryota, Tanaka, Fumine, Umino, Maki, Takeoka, Mami, Hanaki, Ryo, Hirayama, Junya, Yuasa, Hiroto, Imai, Hiroshi, Hirayama, Masahiro, Sakuma, Hajime
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379947/ https://www.ncbi.nlm.nih.gov/pubmed/35982724 http://dx.doi.org/10.1016/j.radcr.2022.07.072

Ejemplares similares

Advanced multiparametric MRI and FDG-PET/CT in multinodular and vacuolating neuronal tumor: A pathologically confirmed case
por: Kishi, Seiya, et al.
Publicado: (2023)

Case Report: ALK-Positive Histiocytosis With KIF5B-ALK Fusion in Cerebrum-Disseminated Lesions in a Child
por: Guo, Yi, et al.
Publicado: (2022)

Hemangioblastoma of the Cerebellopontine Angle Evaluated with Pseudocontinuous Arterial Spin Labeling
por: Kishi, Seiya, et al.
Publicado: (2020)

Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery
por: Tanaka, Fumine, et al.
Publicado: (2017)

A case of a rosette-forming glioneuronal tumor arising from the pons with disappearance of contrast enhancement
por: Tanaka, Fumine, et al.
Publicado: (2019)

Tumor blood flow and apparent diffusion coefficient histogram analysis for differentiating malignant salivary tumors from pleomorphic adenomas and Warthin’s tumors
por: Tanaka, Fumine, et al.
Publicado: (2022)

Pseudocontinuous Arterial Spin Labeling: Clinical Applications and Usefulness in Head and Neck Entities
por: Tanaka, Fumine, et al.
Publicado: (2022)

Author Correction: Tumor blood flow and apparent diffusion coefficient histogram analysis for differentiating malignant salivary tumors from pleomorphic adenomas and Warthin’s tumors
por: Tanaka, Fumine, et al.
Publicado: (2022)

ALK-Positive Histiocytosis: A Case Report and Literature Review
por: Jaber, Omar Issa, et al.
Publicado: (2021)

Case Report: Rare Systemic and Aggressive ALK-Positive Histiocytosis With Recurrent Pancreatitis Treating by Alectinib
por: Li, Yanchu, et al.
Publicado: (2022)

Multisystem ALK-positive histiocytosis: a multi-case study and literature review
por: Liu, Wei, et al.
Publicado: (2023)

ALK-positive histiocytosis involving the cavernous sinus: A deceptive radiologic mimic of meningioma
por: Alizadeh, Mohammadreza, et al.
Publicado: (2023)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

Failure of crizotinib based systemic treatment in ALK positive histiocytosis involving the central nervous system: a case report and literature review
por: He, Qiang, et al.
Publicado: (2022)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

A case of ALK-positive histiocytosis with multiple lesions in the unilateral breast: A case report
por: Kurita, Arisa, et al.
Publicado: (2022)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

The role of Alk-1 and Alk-5 in the mechanosensing of chondrocytes
por: Sanz-Ramos, Patricia, et al.
Publicado: (2014)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Expansion of the ω‐oxidation system AlkBGTL of Pseudomonas putida GPo1 with AlkJ and AlkH results in exclusive mono‐esterified dicarboxylic acid production in E. coli
por: van Nuland, Youri M., et al.
Publicado: (2017)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

Response to ALK‐TKIs in a lung adenocarcinoma patient harboring dual DCTN1‐ALK and ALK‐CLIP4 rearrangements
por: Gao, Fangfang, et al.
Publicado: (2022)

Peptides derived from the dependence receptor ALK are proapoptotic for ALK-positive tumors
por: Aubry, A, et al.
Publicado: (2015)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

SMPD3‐ALK: A novel ALK fusion gene in lung adenocarcinoma
por: Liang, Yuepei, et al.
Publicado: (2021)

Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy
por: Kyi, Chrisann, et al.
Publicado: (2021)

Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
por: Iannantuono, Giovanni Maria, et al.
Publicado: (2022)

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
por: Furugaki, Koh, et al.
Publicado: (2021)

Inhibiting ALK2/ALK3 Signaling to Differentiate and Chemo-Sensitize Medulloblastoma
por: Filipponi, Doria, et al.
Publicado: (2022)

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
por: Duijkers, Floor A. M., et al.
Publicado: (2011)

22. COMPARATIVE EFFICACY OF ALK-INHIBITORS IN ALK INHIBITOR-NAIVE ALK+ LUNG CANCER BRAIN METASTASES: A NETWORK META-ANALYSIS
por: Haddad, Philip, et al.
Publicado: (2020)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
por: Zdzalik, Daria, et al.
Publicado: (2014)

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
por: Deng, Lei, et al.
Publicado: (2018)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jfiupmtvhnruei3ago2o2p8u4n